Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
May 20 2022 - 6:30AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, presented
data demonstrating that the clinical stage selective IRAK4 degrader
KT-474 degrades IRAK4 and inhibits cytokine production in different
immune and skin cell types at the Society of Investigative
Dermatology (SID) Annual Meeting 2022, taking place from May 18 -
21, 2022 in Portland, Oregon.
The poster presentation highlights the broad impact of KT-474
across multiple disease-relevant cell types and supports the
continued development of IRAK4 degraders in patients with HS, AD
and other IL-1R/TLR-driven autoimmune diseases of the skin where
IRAK4 plays a central role in the pathogenesis of inflammation.
“We have found that KT-474 effectively degrades IRAK4 in both
circulating immune cells and resident skin cells such as
keratinocytes and fibroblasts, albeit interestingly with different
kinetics,” said Anthony Slavin, Vice President, Immunology. “These
findings are aligned with what we have observed in our Phase 1
clinical study of KT-474 in healthy volunteers, which showed near
complete IRAK4 degradation in peripheral blood mononuclear cells
and skin following multiple daily doses and robust ex vivo
inhibition of multiple disease-relevant cytokines.”
Poster at SID Annual
Meeting:
- Title: Kinetics of IRAK4 degradation and impact on functional
response in circulating immune cells and skin cell subsets
- Abstract Number: LB993
- Session Day/Time: May 19, 2022; 4:30-6:30pm PT
- Location: Oregon Convention Center, Portland, OR
- Presenter: Emily Lurier, PhD, Senior Scientist, Immunology,
Kymera Therapeutics
- Additional Research Highlights:
- Similar to peripheral blood mononuclear cells (PBMCs), KT-474
achieved IRAK4 degradation in fibroblasts and keratinocytes, with
varying kinetics across cell types
- Maximal degradation was observed after 24 hours of treatment in
PBMCs and fibroblasts, while maximum degradation occurred in
keratinocytes after 96 hours of degrader treatment
- IRAK4 degradation in immune and cutaneous cell types inhibited
pro-inflammatory cytokine production (IL-6 and IL-8) following
IL-1β stimulation
- Previously disclosed results from the multiple ascending dose
(MAD) portion of the Phase 1 trial of KT-474 in healthy volunteers
showed robust degradation of IRAK4 in both PBMC and skin
biopsies
Kymera is collaborating with Sanofi on the development of
degrader candidates targeting IRAK4, including KT-474 (SAR444656),
for indications outside of oncology and immuno-oncology.
About Kymera TherapeuticsKymera Therapeutics
(Nasdaq: KYMR) is a biopharmaceutical company pioneering the field
of targeted protein degradation, a transformative approach to
address disease targets and pathways inaccessible with conventional
therapeutics. Kymera’s Pegasus platform is a powerful drug
discovery engine, advancing novel small molecule therapies that
harness the body’s innate protein recycling machinery to degrade
dysregulated, disease-causing proteins. With a focus on undrugged
nodes in validated pathways, Kymera is advancing a pipeline of
novel therapeutics designed to address the most intractable
pathways and provide new treatments for patients. Kymera’s initial
programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or
JAK/STAT pathways, providing the opportunity to treat patients with
a broad range of immune-inflammatory diseases, hematologic
malignancies, and solid tumors. For more information, visit
www.kymeratx.com.
Founded in 2016, Kymera is headquartered in Watertown, Mass.
Kymera has been named a “Fierce 15” biotechnology company by Fierce
Biotech and has been recognized by the Boston Business Journal as
one of Boston’s “Best Places to Work.” For more information about
our people, science, and pipeline, please visit www.kymeratx.com or
follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
implied and express statements regarding its: strategy, business
plans and objectives for the IRAK4 degrader program; and plans and
timelines for the clinical development of Kymera Therapeutics'
product candidates, including the therapeutic potential and
clinical benefits thereof. The words "may," “might,” "will,"
"could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," “expect,” "estimate," “seek,” "predict,"
“future,” "project," "potential," "continue," "target" and similar
words or expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks associated with: the impact of COVID-19 on
countries or regions in which we have operations or do business, as
well as on the timing and anticipated results of our current
preclinical studies and future clinical trials, strategy and future
operations; the delay of any current preclinical studies or future
clinical trials or the development of Kymera
Therapeutics' drug candidates; the risk that the results
of current preclinical studies may not be predictive of future
results in connection with future clinical trials; Kymera
Therapeutics' ability to successfully demonstrate the safety and
efficacy of its drug candidates; the timing and outcome of the
Company’s planned interactions with regulatory authorities; and
obtaining, maintaining and protecting its intellectual
property. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in the Quarterly Report on Form 10-Q for the period ended March 31,
2022, filed on May 3, 2022, as well as discussions of potential
risks, uncertainties, and other important factors in Kymera
Therapeutics' subsequent filings with the Securities and Exchange
Commission. In addition, any forward-looking statements represent
Kymera Therapeutics' views only as of today and should not be
relied upon as representing its views as of any subsequent date.
Kymera Therapeutics explicitly disclaims any obligation to update
any forward-looking statements. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Investor Contact:Bruce Jacobs Chief Financial
Officer investors@kymeratx.com857-285-5300
Chris BrinzeyManaging Director,
Westwickechris.brinzey@westwicke.com339-970-2843
Media Contact:Todd Cooper Senior Vice
President, Corporate Affairs media@kymeratx.com857-285-5300
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jul 2023 to Jul 2024